Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) France

Research

Date range: 1 April 2021 - 31 March 2022

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) published between 1 April 2021 - 31 March 2022 which are tracked by the Nature Index.

Hover over the donut graph to view the Share for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

Article Count and Share for Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)
Count Share
4 0.46

Outputs by subject (Share)

Outputs by subject
Subject Count Share
3 0.34
3 0.40

Share output for the past 5 years

Share per year
2016 2017 2018 2019 2020
0.00 0.00 0.00 0.00 0.45

Compare Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) with other institutions

Collaboration

Date range: 1 April 2021 - 31 March 2022

International vs. domestic collaboration by Share

  • 88.33% Domestic
  • 11.67% International

Hover over the graph to view the percentage of collaboration.


Top 10 domestic collaborators with Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) by Share (52 total)

  1. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and University of Lille Nord de France (1.71)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)1.01
    University of Lille Nord de France0.70
  2. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and National Institute for Health and Medical Research (INSERM) (1.55)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)1.01
    National Institute for Health and Medical Research (INSERM)0.54
  3. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and French National Centre for Scientific Research (CNRS) (1.47)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)1.01
    French National Centre for Scientific Research (CNRS)0.46
  4. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and Centre Hospitalier Universitaire de Lille (CHU Lille) (1.33)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)1.01
    Centre Hospitalier Universitaire de Lille (CHU Lille)0.31
  5. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and Pasteur Institute (1.23)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)1.01
    Pasteur Institute0.22
  6. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and Centre Oscar Lambret (1.23)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)1.01
    Centre Oscar Lambret0.22
  7. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and Centrale Lille (0.76)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)0.67
    Centrale Lille0.09
  8. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and Center for Infection and Immunity of Lille (CIIL) (0.64)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)0.55
    Center for Infection and Immunity of Lille (CIIL)0.10
  9. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and European Genomic Institute for Diabetes (EGID) (0.64)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)0.55
    European Genomic Institute for Diabetes (EGID)0.10
  10. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and Institute of Electronics, Microelectronics and Nanotechnology (IEMN) (0.62)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)0.55
    Institute of Electronics, Microelectronics and Nanotechnology (IEMN)0.07

Top 10 international collaborators with Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) by Share (10 total)

  1. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and The University of North Carolina at Chapel Hill (UNC) (0.86)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)0.07
    The University of North Carolina at Chapel Hill (UNC)0.79
  2. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and University of Dundee (0.38)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)0.06
    University of Dundee0.31
  3. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and University of Leeds (0.34)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)0.06
    University of Leeds0.28
  4. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and University of Bern (UniBE) (0.24)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)0.21
    University of Bern (UniBE)0.04
  5. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and New York University (NYU) (0.24)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)0.21
    New York University (NYU)0.04
  6. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and Catholic University of Leuven (KU Leuven) (0.24)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)0.21
    Catholic University of Leuven (KU Leuven)0.04
  7. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and Lebanese University (LU) (0.22)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)0.21
    Lebanese University (LU)0.01
  8. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and The University of Manchester (UoM) (0.21)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)0.07
    The University of Manchester (UoM)0.14
  9. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and University of Osnabrück (Uni Osnabrück) (0.19)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)0.06
    University of Osnabrück (Uni Osnabrück)0.13
  10. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and Los Alamos National Laboratory (LANL) (0.09)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)0.06
    Los Alamos National Laboratory (LANL)0.03

Relationships

Partner Institutions

Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) is a research collaboration whose article contributions are accrued to its participating partner institutions below.